The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling
Open accessAbstract
The MAPKs are important transducers of growth and stress stimuli in virtually all eukaryotic cell types. In the mammalian heart, MAPK signaling pathways have been hypothesized to regulate myocyte growth in response to developmental signals or physiologic and pathologic stimuli. Here we generated cardiac-specific transgenic mice expressing dominant-negative mutants of p38alpha, MKK3, or MKK6. Remarkably, attenuation of cardiac p38 activity produced a progressive growth response and myopathy in the heart that correlated with the degree of enzymatic inhibition. Moreover, dominant-negative p38alpha, MKK3, and MKK6 transgenic mice each showed enhanced cardiac hypertrophy following aortic banding, Ang II infusion, isoproterenol infusion, or phenylephrine infusion for 14 days. A mechanism underlying this enhanced-growth profile was suggested by the observation that dominant-negative p38alpha directly augmented nuclear factor of activated T cells (NFAT) transcriptional activity and its nuclear translocation. In vivo, NFAT-dependent luciferase reporter transgenic mice showed enhanced activation in the presence of the dominant-negative p38alpha transgene before and after the onset of cardiac hypertrophy. More significantly, genetic disruption of the calcineurin Abeta gene rescued hypertrophic cardiomyopathy and depressed functional capacity observed in p38-inhibited mice. Collectively, these observations indicate that reduced p38 signaling in the heart promotes myocyte growth through a mechanism involving enhanced calcineurin-NFAT signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Molkentin, J. D., Lu, J.-R., Antos, C. L., Markham, B., Richardson, J., Robbins, J., Grant, S. R., & Olson, E. N. (1998) · Cell · doi:10.1016/s0092-8674(00)81573-1 · Cited by 2,566
Self-citationThe epidemiology of heart failure: The Framingham Study
Ho, K. K. L., Pinsky, J. L., Kannel, W. B., & Levy, D. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90455-a · Cited by 2,247
TAK1 is a ubiquitin-dependent kinase of MKK and IKK
Wang, C., Deng, L., Hong, M., Akkaraju, G. R., Inoue, J.-I., & Chen, Z. J. (2001) · Nature · doi:10.1038/35085597 · Cited by 2,125
Raingeaud, J., Whitmarsh, A. J., Barrett, T., Dérijard, B., & Davis, R. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1247 · Cited by 1,278
Organization and regulation of mitogen-activated protein kinase signaling pathways
Garrington, T. P., & Johnson, G. L. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80028-3 · Cited by 1,275
Left Ventricular Hypertrophy: Pathogenesis, Detection, and Prognosis
Lorell, B. H., & Carabello, B. A. (2000) · Circulation · doi:10.1161/01.cir.102.4.470 · Cited by 1,232
Wang, Y., Huang, S., Sah, V. P., Ross, J., Brown, J. H., Han, J., & Chien, K. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.4.2161 · Cited by 842
Cytoplasmic Signaling Pathways That Regulate Cardiac Hypertrophy
Molkentin, J. D., & Dorn II, G. W. (2001) · Annual Review of Physiology · doi:10.1146/annurev.physiol.63.1.391 · Cited by 689
Self-citationEnslen, H., Raingeaud, J., & Davis, R. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1741 · Cited by 539
Cited by
Regulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866
Self-citationp38 MAP-Kinases pathway regulation, function and role in human diseases
Cuenda, A., & Rousseau, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.03.010 · Cited by 1,400
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Rose, B. A., Force, T., & Wang, Y. (2010) · Physiological Reviews · doi:10.1152/physrev.00054.2009 · Cited by 723
Molecular Pathways Underlying Cardiac Remodeling During Pathophysiological Stimulation
Kehat, I., & Molkentin, J. D. (2010) · Circulation · doi:10.1161/circulationaha.110.942268 · Cited by 592
Self-citationCardiac Myocyte Cell Cycle Control in Development, Disease, and Regeneration
Ahuja, P., Sdek, P., & MacLellan, W. R. (2007) · Physiological Reviews · doi:10.1152/physrev.00032.2006 · Cited by 568
McMullen, J. R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M. C., Kang, P. M., & Izumo, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934654100 · Cited by 534
MOLKENTIN, J. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.01.021 · Cited by 497
Self-citationMAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets
Muslin, A. J. (2008) · Clinical Science · doi:10.1042/cs20070430 · Cited by 494
Jin, Q., Li, R., Hu, N., Xin, T., Zhu, P., Hu, S., Ma, S., Zhu, H., Ren, J., & Zhou, H. (2018) · Redox Biology · doi:10.1016/j.redox.2017.11.004 · Cited by 463
Signaling effectors underlying pathologic growth and remodeling of the heart
van Berlo, J. H., Maillet, M., & Molkentin, J. D. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62839 · Cited by 445
Self-citationCalcium–calcineurin signaling in the regulation of cardiac hypertrophy
Wilkins, B. J., & Molkentin, J. D. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.121 · Cited by 440
Self-citationGATA transcription factors in the developing and adult heart
PIKKARAINEN, S. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.03.025 · Cited by 416
Jones, S. W., Hill, R. J., Krasney, P. A., O'Conner, B., Peirce, N., & Greenhaff, P. L. (2004) · The FASEB Journal · doi:10.1096/fj.03-1228fje · Cited by 407
Control of the size of the human muscle mass
Rennie, M. J., Wackerhage, H., Spangenburg, E. E., & Booth, F. W. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.052102.134444 · Cited by 399
Goodridge, H. S., Simmons, R. M., & Underhill, D. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.3107 · Cited by 357
STRESS signaling pathways that modulate cardiac myocyte apoptosis
BAINES, C., & MOLKENTIN, J. (2005) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2004.11.004 · Cited by 333
Self-citationMolecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision
Iqubal, A., Iqubal, M. K., Sharma, S., Ansari, M. A., Najmi, A. K., Ali, S. M., Ali, J., & Haque, S. E. (2019) · Life Sciences · doi:10.1016/j.lfs.2018.12.018 · Cited by 328
Mitogen-Activated Protein Kinases in Heart Development and Diseases
Wang, Y. (2007) · Circulation · doi:10.1161/circulationaha.106.679589 · Cited by 315
Muchir, A., Pavlidis, P., Decostre, V., Herron, A. J., Arimura, T., Bonne, G., & Worman, H. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29042 · Cited by 309
Yokota, T., & Wang, Y. (2016) · Gene · doi:10.1016/j.gene.2015.09.030 · Cited by 127
Pathway analysis of dilated cardiomyopathy using global proteomic profiling and enrichment maps
Isserlin, R., Merico, D., Alikhani‐Koupaei, R., Gramolini, A., Bader, G. D., & Emili, A. (2010) · PROTEOMICS · doi:10.1002/pmic.200900412 · Cited by 63
Metadata
- Authors
- Braz, J. C., Bueno, O. F., Liang, Q., Wilkins, B. J., Dai, Y.-S., Parsons, S., Braunwart, J., Glascock, B. J., Klevitsky, R., Kimball, T. F., Hewett, T. E., & Molkentin, J. D.
- Venue
- Journal of Clinical Investigation
- Published
- 2003-05-15
- Volume
- 111
- Issue
- 10
- Pages
- 1475-1486
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2134686559
- Cited by
- 332
- References
- 43
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.